Annual Total Long Term Liabilities
$21.04 M
-$11.71 M-35.76%
31 December 2023
Summary:
Lineage Cell Therapeutics annual total long term liabilities is currently $21.04 million, with the most recent change of -$11.71 million (-35.76%) on 31 December 2023. During the last 3 years, it has risen by +$15.98 million (+316.31%). LCTX annual total long term liabilities is now -42.42% below its all-time high of $36.53 million, reached on 31 December 2021.LCTX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$17.94 M
-$2.72 M-13.15%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly total long term liabilities is currently $17.94 million, with the most recent change of -$2.72 million (-13.15%) on 30 September 2024. Over the past year, it has dropped by -$5.68 million (-24.04%). LCTX quarterly long term liabilities is now -50.90% below its all-time high of $36.53 million, reached on 31 December 2021.LCTX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -35.8% | -24.0% |
| 3 y3 years | +316.3% | +533.3% |
| 5 y5 years | +708.5% | +58.8% |
LCTX Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -42.4% | +316.3% | -50.9% | +533.3% |
| 5 y | 5 years | -42.4% | +708.5% | -50.9% | +533.3% |
| alltime | all time | -42.4% | >+9999.0% | -50.9% | >+9999.0% |
Lineage Cell Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $17.94 M(-13.2%) |
| June 2024 | - | $20.65 M(+0.2%) |
| Mar 2024 | - | $20.60 M(-2.1%) |
| Dec 2023 | $21.04 M(-35.8%) | $21.04 M(-10.9%) |
| Sept 2023 | - | $23.61 M(-3.1%) |
| June 2023 | - | $24.38 M(-9.6%) |
| Mar 2023 | - | $26.96 M(-17.7%) |
| Dec 2022 | $32.75 M(-10.4%) | $32.75 M(+6.1%) |
| Sept 2022 | - | $30.86 M(+5.2%) |
| June 2022 | - | $29.33 M(-15.5%) |
| Mar 2022 | - | $34.71 M(-5.0%) |
| Dec 2021 | $36.53 M(+623.0%) | $36.53 M(+1189.9%) |
| Sept 2021 | - | $2.83 M(-35.4%) |
| June 2021 | - | $4.38 M(-7.4%) |
| Mar 2021 | - | $4.74 M(-6.3%) |
| Dec 2020 | $5.05 M(-34.7%) | $5.05 M(-2.0%) |
| Sept 2020 | - | $5.16 M(-24.9%) |
| June 2020 | - | $6.87 M(-4.0%) |
| Mar 2020 | - | $7.16 M(-7.5%) |
| Dec 2019 | $7.74 M(+197.3%) | $7.74 M(-31.5%) |
| Sept 2019 | - | $11.30 M(-6.4%) |
| June 2019 | - | $12.07 M(-12.2%) |
| Mar 2019 | - | $13.76 M(+428.7%) |
| Dec 2018 | $2.60 M(+24.0%) | $2.60 M(+29.1%) |
| Sept 2018 | - | $2.02 M(+21.7%) |
| June 2018 | - | $1.66 M(-22.2%) |
| Mar 2018 | - | $2.13 M(+1.5%) |
| Dec 2017 | $2.10 M(-34.7%) | $2.10 M(-69.4%) |
| Sept 2017 | - | $6.87 M(+319.3%) |
| June 2017 | - | $1.64 M(-75.5%) |
| Mar 2017 | - | $6.70 M(+108.4%) |
| Dec 2016 | $3.21 M(-44.1%) | $3.21 M(+7.3%) |
| Sept 2016 | - | $3.00 M(+4.3%) |
| June 2016 | - | $2.87 M(-58.1%) |
| Mar 2016 | - | $6.85 M(+19.2%) |
| Dec 2015 | $5.75 M(+12.6%) | $5.75 M(+2.9%) |
| Sept 2015 | - | $5.59 M(+2.2%) |
| June 2015 | - | $5.47 M(+37.1%) |
| Mar 2015 | - | $3.99 M(-21.9%) |
| Dec 2014 | $5.11 M(-40.0%) | $5.11 M(-53.2%) |
| Sept 2014 | - | $10.91 M(-23.9%) |
| June 2014 | - | $14.33 M(+105.8%) |
| Mar 2014 | - | $6.96 M(-18.2%) |
| Dec 2013 | $8.51 M(+700.2%) | $8.51 M(+859.4%) |
| Sept 2013 | - | $887.00 K(-5.8%) |
| June 2013 | - | $941.50 K(-7.6%) |
| Mar 2013 | - | $1.02 M(-4.1%) |
| Dec 2012 | $1.06 M(-13.2%) | $1.06 M(-2.1%) |
| Sept 2012 | - | $1.09 M(-3.5%) |
| June 2012 | - | $1.12 M(-4.8%) |
| Mar 2012 | - | $1.18 M(-3.6%) |
| Dec 2011 | $1.22 M | $1.22 M(-1.0%) |
| Sept 2011 | - | $1.24 M(-5.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2011 | - | $1.30 M(-4.2%) |
| Mar 2011 | - | $1.36 M(-0.7%) |
| Dec 2010 | $1.37 M(+11.7%) | $1.37 M(+26.0%) |
| Sept 2010 | - | $1.09 M(-3.3%) |
| June 2010 | - | $1.12 M(-3.2%) |
| Mar 2010 | - | $1.16 M(-5.4%) |
| Dec 2009 | $1.22 M(-38.9%) | $1.22 M(-69.3%) |
| Sept 2009 | - | $3.98 M(+68.6%) |
| June 2009 | - | $2.36 M(+9.7%) |
| Mar 2009 | - | $2.15 M(+7.4%) |
| Dec 2008 | $2.00 M(+13.6%) | $2.00 M(+6.5%) |
| Sept 2008 | - | $1.88 M(+11.4%) |
| June 2008 | - | $1.69 M(-2.2%) |
| Mar 2008 | - | $1.73 M(-2.0%) |
| Dec 2007 | $1.76 M(-7.2%) | $1.76 M(-7.9%) |
| Sept 2007 | - | $1.92 M(+0.4%) |
| June 2007 | - | $1.91 M(+0.4%) |
| Mar 2007 | - | $1.90 M(0.0%) |
| Dec 2006 | $1.90 M(+31.1%) | $1.90 M(-0.1%) |
| Sept 2006 | - | $1.90 M(-0.1%) |
| June 2006 | - | $1.90 M(-2.3%) |
| Mar 2006 | - | $1.95 M(+34.5%) |
| Dec 2005 | $1.45 M(+114.5%) | $1.45 M(+0.1%) |
| Sept 2005 | - | $1.45 M(+20.3%) |
| June 2005 | - | $1.20 M(+35.7%) |
| Mar 2005 | - | $886.40 K(+31.3%) |
| Dec 2004 | $675.30 K(+65.6%) | $675.30 K(+8.1%) |
| Sept 2004 | - | $624.50 K(-8.1%) |
| June 2004 | - | $679.70 K(+72.6%) |
| Mar 2004 | - | $393.70 K(-3.5%) |
| Dec 2003 | $407.80 K(-81.2%) | $407.80 K(-3.3%) |
| Sept 2003 | - | $421.90 K(-84.3%) |
| June 2003 | - | $2.69 M(-2.6%) |
| Mar 2003 | - | $2.76 M(+27.2%) |
| Dec 2002 | $2.17 M(+25.3%) | $2.17 M(+6.2%) |
| Sept 2002 | - | $2.04 M(+5.9%) |
| June 2002 | - | $1.93 M(+5.7%) |
| Mar 2002 | - | $1.82 M(+5.4%) |
| Dec 2001 | $1.73 M(>+9900.0%) | $1.73 M(+1631.1%) |
| Mar 1999 | - | $100.00 K(0.0%) |
| Dec 1998 | $9500.00(-98.1%) | - |
| Sept 1998 | - | $100.00 K(-50.0%) |
| Dec 1997 | - | $200.00 K(-50.0%) |
| Sept 1997 | - | $400.00 K(-20.0%) |
| June 1997 | $500.00 K(+400.0%) | $500.00 K(-600.0%) |
| Sept 1996 | - | -$100.00 K(-200.0%) |
| June 1996 | $100.00 K(0.0%) | $100.00 K(0.0%) |
| June 1995 | $100.00 K(0.0%) | $100.00 K(0.0%) |
| June 1994 | $100.00 K(0.0%) | $100.00 K(0.0%) |
| Sept 1993 | - | $100.00 K(0.0%) |
| June 1993 | $100.00 K | $100.00 K(0.0%) |
| Mar 1993 | - | $100.00 K(0.0%) |
| Mar 1992 | - | $100.00 K |
FAQ
- What is Lineage Cell Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual total long term liabilities year-on-year change?
- What is Lineage Cell Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly long term liabilities year-on-year change?
What is Lineage Cell Therapeutics annual total long term liabilities?
The current annual total long term liabilities of LCTX is $21.04 M
What is the all time high annual total long term liabilities for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual total long term liabilities is $36.53 M
What is Lineage Cell Therapeutics annual total long term liabilities year-on-year change?
Over the past year, LCTX annual total long term liabilities has changed by -$11.71 M (-35.76%)
What is Lineage Cell Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of LCTX is $17.94 M
What is the all time high quarterly long term liabilities for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly total long term liabilities is $36.53 M
What is Lineage Cell Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, LCTX quarterly total long term liabilities has changed by -$5.68 M (-24.04%)